ARXS Stock Analysis: Arxis, Common Stock | NASDAQ
Aerospace & Defense | NASDAQ, USA | Market Cap: 23.321m USD | 12M Return: 44.6% | US04339D1054 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 47.3M
Rev. Trend: 99.6%
Warnings
Tailwinds
Seasonality 0.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arxis, Inc. (NASDAQ: ARXS) is a U.S.-based designer and manufacturer of electronic and mechanical components built for mission-critical applications. The company operates through two reporting segments: Electronic Components, which supplies engineered interconnect solutions such as connectors, cable assemblies, microelectronic packaging, RF and microwave products, power products, sensors, capacitors, and resistors; and Mechanical Components, which provides precision and self-lubricating bearings, seals, springs, gaskets, ducting, and radar absorbing materials.
Arxis serves a diversified customer base across defense and space systems, commercial aerospace platforms, medical technology, semiconductor testing, analytical devices, industrial automation, and other specialized industrial sectors. The company was founded in 2019 and is headquartered in Bloomfield, Connecticut.
Classified within the Industrials sector and the Aerospace & Defense sub-industry, Arxis operates as a components supplier to original equipment manufacturers rather than a prime contractor, meaning its revenue is tied to the build cycles and platform programs of its customers. Suppliers in this segment typically face long product qualification timelines and high switching costs, which tend to support sticky customer relationships once components are designed into a program.
- Defense and space budget growth drives electronic components revenue
- Commercial aerospace production ramp lifts mechanical components demand
- Margin expansion from engineered interconnect pricing power and operating leverage
| Net Income: 102.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 3.52 > 1.0 |
| NWC/Revenue: 54.70% < 20% (prev 60.44%; Δ -5.73% < -1%) |
| CFO/TA 0.05 > 3% & CFO 391.3m > Net Income 102.9m |
| Net Debt (1.46b) to EBITDA (559.6m): 2.61 < 3 |
| Current Ratio: 4.70 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (404.3m) vs prev 0.00% < -2% |
| Gross Margin: 52.03% > 18% (prev 44.57%; Δ 7.47% > 0.5%) |
| Asset Turnover: 26.78% > 50% (prev 11.76%; Δ 15.02% > 0%) |
| Interest Coverage Ratio: 2.27 > 6 (EBIT TTM 359.5m / Interest Expense TTM 158.6m) |
| A: 0.13 (Total Current Assets 1.34b - Total Current Liabilities 284.5m) / Total Assets 8.05b |
| B: 0.01 (Retained Earnings 67.6m / Total Assets 8.05b) |
| C: 0.05 (EBIT TTM 359.5m / Avg Total Assets 7.19b) |
| D: 1.98 (Book Value of Equity 5.35b / Total Liabilities 2.70b) |
| Altman-Z'' = 3.30 = A |
| DSRI: 0.61 (Receivables 315.9m/199.0m, Revenue 1.92b/743.0m) |
| GMI: 0.86 (GM 44.57% / 52.03%) |
| AQI: 0.95 (AQ_t 0.77 / AQ_t-1 0.81) |
| SGI: 2.59 (Revenue 1.92b / 743.0m) |
| TATA: -0.04 (NI 102.9m - CFO 391.3m) / TA 8.05b) |
| Beneish M = -2.37 (Cap -4..+1) = BBB |
As of October 30, 2026, the stock is trading at USD 54.93 with a total of 2,067,790 shares traded. Over the past week, the price has changed by +10.57%, over one month by +11.53%, over three months by +29.34% and over the past year by +44.55%.
Current recommended Stop Loss: 52.30 (which is 4.8% or 1.1 ATR below the current price).
Arxis, Common Stock has received a consensus analysts rating of 4.82. Therefore, it is recommended to buy ARXS.
- StrongBuy: 9
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 63.7 | 16% |
P/E Trailing = 676.625
P/E Forward = 41.6667
P/S = 13.1749
P/B = 5.0725
Revenue TTM = 1.92b USD
EBIT TTM = 359.5m USD
EBITDA TTM = 559.6m USD
Long Term Debt = 1.88b USD (from longTermDebt, last fiscal year)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 1.95b USD (corrected: LT Debt 1.88b + ST Debt 12.2m) + Leases 65.2m
Net Debt = 1.46b USD (calculated: Debt 1.95b - CCE 493.7m)
Enterprise Value = 24.8b USD (23.3b + Debt 1.95b - CCE 493.7m)
Interest Coverage Ratio = 2.27 (Ebit TTM 359.5m / Interest Expense TTM 158.6m)
EV/FCF = 73.55x (Enterprise Value 24.8b / FCF TTM 336.9m)
FCF Yield = 1.36% (FCF TTM 336.9m / Enterprise Value 24.8b)
FCF Margin = 17.51% (FCF TTM 336.9m / Revenue TTM 1.92b)
Net Margin = 5.35% (Net Income TTM 102.9m / Revenue TTM 1.92b)
Gross Margin = 52.03% ((Revenue TTM 1.92b - Cost of Revenue TTM 922.9m) / Revenue TTM)
Gross Margin QoQ = 54.27% (prev 52.44%)
Tobins Q-Ratio = 3.08 (Enterprise Value 24.8b / Total Assets 8.05b)
Interest Expense / Debt = 8.12% (Interest Expense 158.6m / Debt 1.95b)
Taxrate = 30.08% (36.0m / 119.7m)
NOPAT = 251.3m (EBIT 359.5m * (1 - 30.08%))
Current Ratio = 4.70 (Total Current Assets 1.34b / Total Current Liabilities 284.5m)
Debt / Equity = 0.37 (Debt 1.95b / totalStockholderEquity, last quarter 5.35b)
Debt / EBITDA = 2.61 (Net Debt 1.46b / EBITDA 559.6m)
Debt / FCF = 4.33 (Net Debt 1.46b / FCF TTM 336.9m)
Total Stockholder Equity = 4.20b (last fiscal year from totalStockholderEquity)
RoA = 1.43% (Net Income 102.9m / Total Assets 8.05b)
RoE = 2.45% (Net Income TTM 102.9m / Total Stockholder Equity 4.20b)
RoCE = 5.92% (EBIT 359.5m / Capital Employed (Equity 4.20b + L.T.Debt 1.88b))
RoIC = 3.27% (NOPAT 251.3m / Invested Capital 7.68b)
WACC = 14.61% (E(23.3b)/V(25.3b) * Re(15.36%) + D(1.95b)/V(25.3b) * Rd(8.12%) * (1-Tc(0.30)))
Discount Rate = 15.36% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
[DCF] Terminal Value 60.41% ; FCFF base≈219.0m ; Y1≈251.0m ; Y5≈369.4m
[DCF] Fair Price = 12.84 (EV 2.62b - Net Debt 1.46b = Equity 1.16b / Shares 90.1m; r=14.61% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.59 | Revenue CAGR: 94.21% | SUE: N/A | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.30 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=1.04 | Chg30d=+0.27% | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+28.9%
EPS next Year (2027-12-31): EPS=1.34 | Chg30d=-1.65% | Revisions=+40% | GrowthEPS=+28.0% | GrowthRev=+18.6%
[Analyst] Revisions Ratio: +40% (up=2, down=0)